Accepted Articles
Back to the articles list |
Back to browse issues page
Sahar Bayat1 
, Milad Gholami2 , Hamidreza Khodadadi3 , Mohammadreza Ghazavi4 , Jafar Nasiri4 , Majid Kheirollahi * 1
, Milad Gholami2 , Hamidreza Khodadadi3 , Mohammadreza Ghazavi4 , Jafar Nasiri4 , Majid Kheirollahi * 1
1- Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
2- Department of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arāk, Iran.
3- Department of Biotechnology, School of Medicine, Lorestan University of Medical Sciences, Lorestan, Iran
4- Department of Pediatric Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2- Department of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arāk, Iran.
3- Department of Biotechnology, School of Medicine, Lorestan University of Medical Sciences, Lorestan, Iran
4- Department of Pediatric Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract:
Background: Hypomyelinating leukodystrophie-5 (HLD-5) is a rare multiple congenital anomaly with intellectual disability caused by an autosomal recessive mutation in the FAM126A gene and is characterized by bilateral congenital cataract, developmental delay, cerebellar ataxia, slowly progressive gait disturbance and cognitive impairment. This study aims to contribute to a better understanding of HLD-5 by reviewing previous patients and introducing a novel variant in a new case.
Methods and Results: We subjected a case with an initial diagnosis of HLD-5 in an Iranian family. To identify the possible genetic cause(s), whole exome sequencing (WES) was carried out to detect exon mutations and Sanger sequencing was performed to verify the DNA sequence variants and co-segregation analysis. We predicted the potential deleterious effects of the novel mutation using in silico predictive tools. WES identified a novel homozygous mutation (NM_032581: c.636_639del p.C213Dfs*7) in the FAM126A gene. The variant can cause premature termination of amino acid translation or affect mRNA expression.
Conclusions: In this study, the clinical manifestations and molecular findings of HLD-5 were explained. Additionally, we reported a novel variant and some rare clinical features, such as exophthalmos and strabismus, in our proband for the first time. Further research is needed to clarify the molecular mechanisms underlying HLD-5 pathogenesis.
Methods and Results: We subjected a case with an initial diagnosis of HLD-5 in an Iranian family. To identify the possible genetic cause(s), whole exome sequencing (WES) was carried out to detect exon mutations and Sanger sequencing was performed to verify the DNA sequence variants and co-segregation analysis. We predicted the potential deleterious effects of the novel mutation using in silico predictive tools. WES identified a novel homozygous mutation (NM_032581: c.636_639del p.C213Dfs*7) in the FAM126A gene. The variant can cause premature termination of amino acid translation or affect mRNA expression.
Conclusions: In this study, the clinical manifestations and molecular findings of HLD-5 were explained. Additionally, we reported a novel variant and some rare clinical features, such as exophthalmos and strabismus, in our proband for the first time. Further research is needed to clarify the molecular mechanisms underlying HLD-5 pathogenesis.
Type of Study: Original |
Subject:
Cellular and molecular Neuroscience
Received: 2024/09/10 | Accepted: 2024/10/26
Received: 2024/09/10 | Accepted: 2024/10/26
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
